Sleep Apnea Clinical Trial Pipeline Expands as 10+ Pharma Companies Progress Novel Therapies Toward Market Entry

DelveInsight's report provides insights into the evolving Sleep Apnea treatment landscape

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

DelveInsight's 'Sleep Apnea – Pipeline Insight, 2026' report provides comprehensive insights about 10+ companies, including Apnimed, RespireRx Pharmaceuticals, Neurim Pharmaceuticals, and others, developing 14+ pipeline drugs in the Sleep Apnea treatment landscape. The report covers the latest breakthroughs, emerging therapies, and the evolving Sleep Apnea pipeline.

Why it matters

The Sleep Apnea pipeline is rapidly expanding with innovative therapeutic approaches targeting the underlying causes of the condition. The emergence of novel treatments could significantly improve outcomes for patients and address the limitations of current standard of care options.

The details

The Sleep Apnea pipeline features diverse therapeutic approaches, including neuromuscular modulators, cannabinoid-based therapies, and peripheral chemoreception modulators. Key pipeline candidates include AD109 by Apnimed, which is in Phase III clinical trials and represents the most advanced investigational oral therapy designed to target neuromuscular dysfunction in obstructive sleep apnea patients. Other promising therapies include Dronabinol by RespireRx Pharmaceuticals and GAL-475 by Neurim Pharmaceuticals, which are in earlier stages of development.

  • In December 2025, Incannex Healthcare received FDA Fast Track designation for IHL-42X (dronabinol + acetazolamide) in OSA, supported by Phase 2 RePOSA trial results showing up to 83% AHI reduction.
  • In October 2025, Apnimed presented additional Phase 3 data from SynAIRgy and LunAIRo trials for AD109 at CHEST 2025, showing improvements in AHI, ODI, and hypoxic burden.
  • In August 2025, FDA approved Nyxoah's Genio hypoglossal nerve stimulation system for moderate-to-severe OSA patients with AHI 15-65, based on the DREAM trial.

The players

Apnimed

A company developing AD109, an investigational oral therapy designed to target the underlying neuromuscular dysfunction in people living with obstructive sleep apnea.

RespireRx Pharmaceuticals

A company developing Dronabinol, a synthetic form of tetrahydrocannabinol (THC) that has shown potential in treating sleep apnea by modulating respiratory control centers and upper airway muscle tone.

Neurim Pharmaceuticals

A company developing GAL-475, a novel therapeutic agent that acts as a peripheral chemoreception modulator to increase respiratory drive and ameliorate obstructive apneas.

Got photos? Submit your photos here. ›

What they’re saying

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The expanding Sleep Apnea pipeline showcases the industry's commitment to addressing the unmet needs in this space. The emergence of novel therapies targeting the underlying causes of the condition could significantly improve outcomes for patients and provide more effective treatment options beyond the current standard of care.